SEC 13F Intelligence

Managers / Q2 2024 · view latest →

Foresite Capital Management IV, LLC

CIK 0001704132 · 9200 W. SUNSET BOULEVARD, SUITE 515, WEST HOLLYWOOD, CA, 90069 · 415-877-4887

Reported Value
$149M
Q2 2024
Positions
4
Filings on Record
30
2019–present window
Filed
Aug 13, 2024
original filing

Summary

Foresite Capital Management IV, LLC reported $149M in U.S.-listed holdings across 4 positions for Q2 2024.

The portfolio is heavily concentrated: Pharvaris N V alone accounts for 54.2% of reported value.

Compared with Q1 2024, the fund opened 0 new positions and exited 1.

Portfolio Metrics

Turnover
0.0%
vs prior filed quarter
Largest Position
+54.2%
Pharvaris N V

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q1 ’19: $278MQ1 ’19Q2 ’19: $354MQ3 ’19: $309MQ4 ’19: $232MQ1 ’20: $81MQ1 ’20Q2 ’20: $205MQ3 ’20: $443MQ4 ’20: $921MQ1 ’21: $835MQ1 ’21Q2 ’21: $740MQ3 ’21: $679MQ4 ’21: $486MQ1 ’22: $357MQ1 ’22Q2 ’22: $371MQ3 ’22: $311MQ4 ’22: $234MQ1 ’23: $193MQ1 ’23Q2 ’23: $203MQ3 ’23: $180MQ4 ’23: $198MQ1 ’24: $198MQ1 ’24Q2 ’24: $149MQ3 ’24: $153MQ4 ’24: $109MQ1 ’25: $111MQ1 ’25Q2 ’25: $124MQ3 ’25: $183MQ4 ’25: $230MQ1 ’26: $237MQ1 ’26filingsflow.com

Portfolio Composition

By security type
Other: 62.3%Common Stock: 37.7%
  • Other · 62.3% · $93M
  • Common Stock · 37.7% · $56M

Quarter-over-Quarter Changes full breakdown →

vs Q1 2024 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
Kinnate Biopharma Inc.SOLD OUT−9.67M0−$26M$0
Pharvaris N.V.ADDED+255.0K4.29M−$13M$81M
Lyell Immunopharma, Inc.HELD+08.32M−$6M$12M
SNDXSyndax Pharmaceuticals, Inc.HELD+0875.0K−$3M$18M
KURAKura Oncology, Inc.HELD+01.85M−$1M$38M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q2 2024

4 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1Pharvaris N.V.COM54.23%$81M4.29M
2KURAKura Oncology, Inc.history →COM25.59%$38M1.85M
3SNDXSyndax Pharmaceuticals, Inc.history →COM12.07%$18M875.0K
4Lyell Immunopharma, Inc.COM8.11%$12M8.32M

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$237M8May 15, 202613F-HRchanges · EDGAR ↗
Q4 2025$230M7Feb 17, 202613F-HRchanges · EDGAR ↗
Q3 2025$183M6Nov 14, 202513F-HRchanges · EDGAR ↗
Q2 2025$124M6Aug 12, 202513F-HRchanges · EDGAR ↗
Q1 2025$111M5May 15, 202513F-HRchanges · EDGAR ↗
Q4 2024$109M4Feb 14, 202513F-HRchanges · EDGAR ↗
Q3 2024$153M5Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$149M4Aug 13, 202413F-HRchanges · EDGAR ↗
Q1 2024$198M5May 15, 202413F-HRchanges · EDGAR ↗
Q4 2023$198M5Feb 13, 202413F-HRchanges · EDGAR ↗
Q3 2023$180M7Nov 13, 202313F-HRchanges · EDGAR ↗
Q2 2023$203M7Aug 11, 202313F-HRchanges · EDGAR ↗
Q1 2023$193M8May 12, 202313F-HRchanges · EDGAR ↗
Q4 2022$234M8Feb 13, 202313F-HRchanges · EDGAR ↗
Q3 2022$311M8Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$371M8Aug 12, 202213F-HRchanges · EDGAR ↗
Q1 2022$357M9May 13, 202213F-HRchanges · EDGAR ↗
Q4 2021$486M9Feb 11, 202213F-HRchanges · EDGAR ↗
Q3 2021$679M12Nov 12, 202113F-HRchanges · EDGAR ↗
Q2 2021$740M13Aug 16, 202113F-HRchanges · EDGAR ↗
Q1 2021$835M13May 17, 202113F-HRchanges · EDGAR ↗
Q4 2020$921M13Feb 16, 202113F-HRchanges · EDGAR ↗
Q3 2020$443M15Nov 13, 202013F-HRchanges · EDGAR ↗
Q2 2020$205M12Aug 13, 202013F-HRchanges · EDGAR ↗
Q1 2020$81M11May 28, 2020RESTATEMENTchanges · EDGAR ↗
Q4 2019$232M14Feb 14, 202013F-HRchanges · EDGAR ↗
Q3 2019$309M19Nov 13, 201913F-HRchanges · EDGAR ↗
Q2 2019$354M22Aug 13, 201913F-HRchanges · EDGAR ↗
Q1 2019$278M16May 14, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.